eCOA software for better clinical trials
eCOAs (electronic Clinical Outcome Assessments) and digital outcome measures delivered at industry-leading speed and quality to enhance your trial findings and fuel medical breakthroughs.
eCOA+ is part of Medable's unified data collection platform, which includes eConsent, telehealth, and sensors, with standardized integrations into your existing clinical ecosystem.
Medable eCOA+
Faster study build time
Pre-built and validated instruments
Available languages
Take eCOA off the critical path
Rapidly deploy quality studies and take eCOA off the critical path of study start-up with a reusable instrument library of 380+ standardized workflows and AI-enabled, purpose-built technology so you can work on what matters most, advancing patient care.
Unlock insights with real-time data capture
Capture objective and subjective participant data in a standardized and compliant manner. Medable’s eCOA+ combines eClinROs, ePROs, ePerfOs, eObsROs, and digital measures, so you can uncover clinically meaningful insights in real-time.
Engage patients with a better experience
Medable’s eCOA clinical trial solution improves inclusivity and accessibility, meeting the needs of patients in any geographic location and across diverse therapeutic areas, reducing burden and increasing retention.
The Medable difference
Reusable eCOA Library
Our library of 380+ reusable, pre-validated instruments, assessments and diaries ensure a standardized, consistent method of data collection that drives real-time decision making.
BYOD and provisioned devices
Accessible across web and/or mobile, provisioned devices or BYOD, unlocking patient populations that were previously out of reach while increasing patients' optionality.
Cross-platform TeleVisit
One seamless platform experience allows site and patient users to better engage and participate in a comfortable environment, reducing burden and increasing compliance.
Digital measures
Standardized integrations for sensors capturing digital physiological measures provide value across a variety of therapeutic areas including Oncology, Immunology, Cardiovascular, and more.
User friendy Platform
Consumer-grade UX, complete with notifications, reports, and submission-ready data, is vetted by our Patient Caregiver Network (PCN) and clinicians, ensuring accessibility.
24/7 Customer Support
Global customer care support throughout your trial for sites, patients and study teams. Our team ensure the best user experience to enable seamless technology adoption, protocol compliance, and overall user satisfaction.
Globally Compliant
Available in 70+ countries and 120+ locales, Medable’s platform adheres to standards set by the FDA, CFR21 Part 11, HIPAA, and GDPR.
Powered by AI
By harnessing intelligent automation, we can reduce delivery timelines by up to 50%, enabling an accelerated study start up to quickly capture novel endpoints.
A top 10 pharmaceutical company approached Medable seeking support for their Phase III diabetes study in the highly competitive weight loss market. Their primary goal was to reduce the client’s average study build timelines from 16-20 weeks, down to just 8 weeks, a reduction of more than 50%.See how Medable was able to meet the customer's goal with this case study.
eCOA+ Streamlined Evidence Generation
Frequently asked questions
eCOA stands for electronic clinical outcome assessment and uses electronic devices like tablets, desktop computers, and phones to collect data from trial participants. Participants complete diaries, questionnaires, or other prompts to communicate how they are feeling or functioning during the course of a clinical trial. eCOAs are part of the decentralized clinical trial (DCT) methodology and are essential to understanding whether a drug is reducing symptoms and improving patients’ quality of life.
Medable’s eCOA offering is part of our broader evidence generation offering: Patient-First Data Collection. Medable’s tools allow teams to build eCOA instruments (both validated instruments and eDiaries) that meet industry standards. Data collected from this system can be used for primary endpoints in pivotal studies. Study teams can store instruments, including translations, in a library for rapid deployment in future studies. Dashboards keep teams informed of all startup activities along the way. Teams may also access their library of prebuilt, validated instruments to improve study startup.
Yes. Medable's platform is multimodal, meaning patients can access our interface through the Patient app or a web browser. A BYOD model allows patients to use their own smartphone or other device for data capture during a site visit or remotely. Participants using devices they are already familiar with may lead to better compliance and ultimately, a better clinical trial experience. However, since some participants may be hesitant to download an app on their own device, or may not own a device that meets the requirements, it’s important to anticipate a percentage of provisioned devices, even in trials adopting a BYOD strategy.
The latest in eCOA
Six steps to help you choose the right clinical trial partner
“This year, we’ve decided to stick to paper. We know what we’re getting and we’ve always done it this way.”
That was the unwavering response from a clinical operations lead at a pioneering biotech when asked why they still relied on paper diaries for patient-reported outcomes.
Despite the growing complexity of global trials, the promise of real-time data, and the surge of digital capabilities available today, some organizations have held tight to a method of clinical trial conduct that’s increasingly as outclassed as it is outdated.
It’s well known that individuals and organizations believe that change can be daunting, stressful, and difficult, especially when the old way is familiar and entrenched. However, much like anything else, having a partner who can help guide you through the process is massively important. But, how do you find the right partner for your trials?
Before locking in a vendor, organizations must engage in a deliberate process to assess their needs, align stakeholders, and set the foundation for long-term success. This blog explores the critical steps sponsors should take before selecting a digital partner, using insights and frameworks drawn from Medable’s therapeutic area standards and industry best practices.
From bottlenecks to breakthroughs: How AI is transforming translation timelines
According to ClinicalTrials.gov, there are 3,046 multi-country trials being conducted this year. While many trials remain localized within a single country, there has been a definitive movement towards conducting trials in multiple countries, especially for larger, later-stage trials. This is driven by the positives that multi-country trials offer, like faster patient recruitment, lower costs in some regions, and the need for diverse patient populations.. However, behind the scenes, a critical bottleneck has been slowing many trials down. This bottleneck is the translation process that’s required to make trials work across multiple languages, locales, and regulatory bodies/organizations.
Case study: Removing translation bottlenecks with AI
Traditionally, translations and language migration create significant bottlenecks on the path to trial study go-live. The process is traditionally manual, linear, and resource intensive. To address these challenges, Medable partnered withLionbridge, a leading translation services company to compare the status quo translation process against an AI-enabled approach powered by both companies’ proprietary new AI tools.